Plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tPA/PAI-1 complex in patients with disseminated intravascular coagulation and thrombotic thrombocytopenic purpura.
In this study, we examined changes in the plasma levels of total plasminogen activator inhibitor-I (PAI-I) and tissue-type plasminogen activator (tPA)/PAI-I complex in patients with disseminated intravascular coagulation (DIC) and in those with thrombotic thrombocytopenic purpura (TTP) to investigate the fibrinolytic function and its relation to organ failure. The plasma levels of total PAI-1 and tPA/PAI-I complex were significantly higher in patients with DIC, pre-DIC, and TTP than in those with non-DIC. The plasma levels of thrombin-antithrombin complex (TAT), plasmin-plasmin inhibitor complex (PPIC), D-dimer, thrombomodulin (TM), total PAI-I, and tPA/PAI-I complex were significantly higher in patients with organ failure than in those without organ failure. The plasma levels of total PAI-I and tPA/PAI-I complex were markedly increased in patients with acute leukemia. The plasma levels of total PAI-I, but not those of tPA/PAI-I complex, were significantly increased in patients with sepsis or with solid cancer. In all cases, total PAI-I or tPA/PAI-I complex was not significantly correlated with any hemostatic marker. Measurement of total PAI-I and tPA/PAI-I complex may be useful in the diagnosis of DIC.
Watanabe
R
R
DepartmentSecond Department of Internal Medicine, Mie University School of Medicine, Tsu-city, Japan.
Wada
H
H
Miura
Y
Y
Murata
Y
Y
Watanabe
Y
Y
Sakakura
M
M
Okugawa
Y
Y
Nakasaki
T
T
Mori
Y
Y
Nishikawa
M
M
Gabazza
E C
EC
Shiku
H
H
Nobori
T
T
D000933:Antifibrinolytic Agents / Q000032:analysis; D000990:Antithrombin III / Q000032:analysis; D015415:Biomarkers; D004211:Disseminated Intravascular Coagulation / Q000097:blood* / Q000150:complications / Q000175:diagnosis; D004730:Endothelium, Vascular / Q000473:pathology; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005341:Fibrinolysin / Q000032:analysis; D005342:Fibrinolysis; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications; D006801:Humans; D046911:Macromolecular Substances; D009102:Multiple Organ Failure / Q000097:blood / Q000209:etiology; D009369:Neoplasms / Q000097:blood / Q000150:complications; D010447:Peptide Hydrolases / Q000032:analysis; D017395:Plasminogen Activator Inhibitor 1 / Q000032:analysis* / Q000378:metabolism; D011485:Protein Binding; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood* / Q000150:complications; D018805:Sepsis / Q000097:blood / Q000150:complications; D018180:Thrombomodulin / Q000097:blood; D010959:Tissue Plasminogen Activator / Q000032:analysis* / Q000378:metabolism; D000979:alpha-2-Antiplasmin / Q000032:analysis
D000933:Antifibrinolytic Agents; D015415:Biomarkers; D005338:Fibrin Fibrinogen Degradation Products; D046911:Macromolecular Substances; D017395:Plasminogen Activator Inhibitor 1; D018180:Thrombomodulin; D000979:alpha-2-Antiplasmin; C046193:antithrombin III-protease complex; C036309:fibrin fragment D; C037742:plasmin-plasmin inhibitor complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator; D005341:Fibrinolysin